• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
Canada

Tag Archive

View Post

Canada Lead the Way with Rare Disease Gene Discovery Project

In Clinical Development by CameronJune 12, 2014

Canada’s Finding Rare Disease Genes (FORGE) program has released the outcome of the two year project this week in the American Journal of Human Genetics. …

Canadian Orphan Drug Market: myths and realities – Medunik Canada

In Orphan Drug Congress by CameronJanuary 24, 2014

Eric Gervais, Executive Vice President of Medunik Canada gives his presentation on ‘Myths and realities of the Canadian orphan drug market’ at the World Orphan …

Why should Canada follow Ontario’s newborn screening initiative?

In Advocacy, Market Access, Regulation & Government by André SingerAugust 29, 2013

Canada’s provincial and territorial disparities in many areas of health care are nothing new. When it comes to treating and preventing rare disorders, that gap …

The life-threatening orphan drugs reimbursement system in Canada

In Advocacy, Clinical Development, Market Access, Regulation & Government by André SingerAugust 8, 2013

According to the Canadian Organization for Rare Disorders (CORD), it has been more difficult to gain access to orphan drugs than it is in other …

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise